BJMO - volume 10, issue 6, september 2016
F. Baekelandt MD, W. Everaerts MD, PhD, M. Albersen MD, PhD, B. Van Cleynenbreugel MD, PhD, U. Milenkovic MD, C. Assenmacher MD, S. Joniau MD, PhD
BRCA2 mutation carriers generally present with prostate cancer at a younger age, with more aggressive disease and with a higher risk of nodal involvement or distant metastases at diagnosis. We present a patient with metastatic castrate resistant prostate cancer with a BRCA2 gene mutation and its clinical significance for daily practice.
(BELG J MED ONCOL 2016;10(6):223–227)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
